Search Results - "REDER, A. T"

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) by Langdon, DW, Amato, MP, Boringa, J, Brochet, B, Foley, F, Fredrikson, S, Hämäläinen, P, Hartung, H-P, Krupp, L, Penner, IK, Reder, AT, Benedict, RHB

“…Background: Cognitive impairment in MS impacts negatively on many patients at all disease stages and in all subtypes. Full clinical cognitive assessment is…”
Get full text

Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology by CELLA, D, LAI, J.-S, REDER, A. T, SUFIT, R, SIMUNI, T, HOLMES, G. L, SIDEROWF, A, WOJNA, V, BODE, R, MCKINNEY, N, PODRABSKY, T, WORTMAN, K, NOWINSKI, C. J, CHOI, S, GERSHON, R, ROTHROCK, N, MOY, C, VICTORSON, D, PETERMAN, A, MILLER, D, BETHOUX, F, HEINEMANN, A, RUBIN, S, CAVAZOS, J. E

“…To address the need for brief, reliable, valid, and standardized quality of life (QOL) assessment applicable across neurologic conditions. Drawing from larger…”
Get full text

Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial by GOODIN, D. S, REDER, A. T, KNAPPERTZ, V, EBERS, G. C, CUTTER, G, KREMENCHUTZKY, M, OGER, J, LANGDON, D, RAMETTA, M, BECKMANN, K, DESIMONE, T. M

“…To examine the effects of interferon beta (IFNβ)-1b on all-cause mortality over 21 years in the cohort of 372 patients who participated in the pivotal…”
Get full text

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis by ZIVADINOV, R, REDER, A. T, FILIPPI, M, MINAGAR, A, STÜVE, O, LASSMANN, H, RACKE, M. K, DWYER, M. G, FROHMAN, E. M, KHAN, O

“…Disease-modifying agents (DMAs), including interferon beta (IFNbeta) and glatiramer acetate (GA), are the mainstays of long-term treatment of multiple…”
Get full text

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis by BIRNBAUM, G, CREE, B, ALTAFULLAH, I, ZINSER, M, REDER, A. T

“…To explore whether high-dose atorvastatin can be administered safely to persons with relapsing-remitting multiple sclerosis (MS) taking thrice weekly, 44…”
Get full text

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial by Ebers, G C, Traboulsee, A, Li, D, Langdon, D, Reder, A T, Goodin, D S, Bogumil, T, Beckmann, K, Wolf, C, Konieczny, A

“…BackgroundEvidence for efficacy of disease-modifying drugs in multiple sclerosis (MS) comes from trials of short duration. We report results from a 16 y,…”
Get full text

Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence : Report report of the therapeutics and technology assessment subcommittee of the american academy of neurology by GOODIN, D. S, FROHMAN, E. M, HURWITZ, B, O'CONNOR, P. W, OGER, J. J, REDER, A. T, STEVENS, J. C

“…The clinical and radiologic impact of developing neutralizing antibodies (NAbs) to interferon beta (IFNbeta) while on this therapy for multiple sclerosis (MS)…”
Get full text

Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis by Banwell, B, Reder, A T, Krupp, L, Tenembaum, S, Eraksoy, M, Alexey, B, Pohl, D, Freedman, M, Schelensky, L, Antonijevic, I

“…Immunomodulatory therapies are widely used in adults with multiple sclerosis (MS) and safety and tolerability is well-established. Although at least 5% of all…”
Get full text

Interferon-β regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis by Hamamcioglu, K., Reder, AT

“…The mechanism of action of interferon (IFN)-β therapy in multiple sclerosis (MS) is only partially known, and its efficacy changes with disease stage. In…”
Get full text

Minor salivary gland inflammation in Devic’s disease and longitudinally extensive myelitis by Javed, A, Balabanov, R, Arnason, BGW, Kelly, TJ, Sweiss, NJ, Pytel, P, Walsh, R, Blair, EA, Stemer, A, Lazzaro, M, Reder, AT

“…Devic’s disease is often considered as a variant of multiple sclerosis (MS). However, evidence suggests that Devic’s disease may be distinct from MS. Devic’s…”
Get full text

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy by Genç, K, Dona, D L, Reder, A T

“…Costimulatory molecules help determine T cell responses. CD80 (B7-1) and CD86 (B7-2), costimulatory proteins on antigen-presenting cells, bind to CD28 on T…”
Get full text

Psychometric evaluation of the Chicago Multiscale Depression Inventory in multiple sclerosis patients by CHANG, C-H, NYENHUIS, D. L, CELLA, D, LUCHETTA, T, DINEEN, K, REDER, A. T

“…The Chicago Multiscale Depression Inventory (CMDI), a comprehensive self-report measure of depression, has proven useful in the assessment of patients with…”
Get full text

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis by Croze, E, Yamaguchi, K D, Knappertz, V, Reder, A T, Salamon, H

“…Interferon beta (IFNβ) reduces disease burden in relapsing-remitting multiple sclerosis (MS) patients. In this study, IFNβ-1b-treated MS patient gene…”
Get full text

Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue by REDER, A. T, ARNASON, B. G. W

“…Trigeminal neuralgia is an uncommon but troublesome symptom of multiple sclerosis that can be refractory to conventional treatments. Misoprostol, a long-acting…”
Get full text

Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS by REDER, A. T, EBERS, G. C, TRABOULSEE, A, LI, D, LANGDON, D, GOODIN, D. S, BOGUMIL, T, BECKMANN, K, KONIECZNY, A

Get full text

Cytokines in the vitreous of patients with proliferative diabetic retinopathy by Abu el Asrar, A M, Maimone, D, Morse, P H, Gregory, S, Reder, A T

“…Sixteen vitreous and paired serum samples from 13 patients with proliferative diabetic retinopathy, vitreous samples from seven cadaveric control subjects, and…”
Get more information

Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis by Chrabot, B S, Kariuki, S N, Zervou, M I, Feng, X, Arrington, J, Jolly, M, Boumpas, D T, Reder, A T, Goulielmos, G N, Niewold, T B

“…Alleles of interferon (IFN) regulatory factor 8 (IRF8) are associated with susceptibility to both systemic lupus erythematosus (SLE) and multiple sclerosis…”
Get full text

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS by Reder, A T, Ebers, G C, Traboulsee, A, Li, D, Langdon, D, Goodin, D S, Bogumil, T, Beckmann, K, Konieczny, A

“…The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-beta-1b (IFNbeta-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes…”
Get full text

Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis by Ahn, James, Feng, Xuan, Patel, Nilesh, Dhawan, Neetu, Reder, A T

“…Interferon-gamma is produced by immune cells before MS exacerbations, and exogenous IFN-gamma treatment causes MS attacks. IFN-beta production, conversely,…”
Get full text

Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b by Pliskin, N H, Hamer, D P, Goldstein, D S, Towle, V L, Reder, A T, Noronha, A, Arnason, B G.W

“…We assessed neuropsychological function longitudinally in 30 MS patients who participated in the pivotal trial of interferon beta-1b (IFN-beta-1b). Nine…”
Get full text